4DMedical (4DX) H2 2025 earnings summary

Executive summary

• Achieved FDA clearance and CMS reimbursement for CT:VQ™, a non-contrast lung imaging software, and FDA clearance for IQ-UIP™, enhancing diagnostic capabilities for interstitial pulmonary fibrosis.

• Signed a transformative five-year reseller agreement with Philips, granting exclusive distribution to US government customers and non-exclusive rights to commercial partners, accelerating US market penetration.

• Secured a $10 million strategic investment from Pro Medicus and raised $13.9 million through share placement and purchase plan, strengthening the balance sheet.

• Expanded global footprint to 388 sites, delivering nearly 200,000 scans in FY25, with SaaS revenue up 95% year-over-year and operating revenue up 56% to $5.9 million.

Financial highlights

• FY25 operating revenue: $5.9 million, up 56% vs FY24; underlying SaaS revenue up 95% year-over-year.

• Other income: $10.6 million, primarily from R&D tax credits and government grants.

• Gross profit margin exceeded 90%.

• Net underlying operating expenditure: $35.7 million, reflecting cost savings from restructuring and integration.

• Receipts from customers: $5.4 million, up 87% year-over-year.

• Net loss after tax: $30.1 million, improved from $36.2 million in FY24.

• Cash and cash equivalents at year-end: $6.9 million.

Outlook and guidance

• Focus on scaling US commercialisation via Philips partnership, targeting Veterans Affairs, Department of Defense, and broader hospital networks.

• Continued expansion in Australia, leveraging national lung cancer screening and radiology networks.

• Ongoing product development and clinical validation, including post-FDA clearance studies for CT:VQ™ and new AI-driven solutions.